Cefoxitin: its role in treatment and prophylaxis of obstetric and gynecologic infections.
Cefoxitin has become one of the most used parenteral antibiotics in the United States, perhaps because of a broad spectrum of activity, including activity against Bacteroides fragilis, which makes the drug suitable for prevention and treatment of intraabdominal and pelvic infections. This review focuses on the use of cefoxitin in obstetric and gynecologic infections, with comparisons to older and newer antibiotics. Numerous studies have shown that cefoxitin is clearly effective; in most of these studies, however, either the initial infection rates were low or the sample sizes were small--circumstances making it difficult to establish the superiority of any one agent. Thus, the necessity of using a drug with activity against B. fragilis for prevention and treatment of pelvic infections has not been proven. Several antibiotics without such activity have been equally effective. Cefoxitin may be of particular value when combined with surgical drainage of pelvic abscesses, infections in which control of B. fragilis may be especially important to outcome.
Counts
G W
GW
Program in Infectious Disease, Fred Hutchinson Cancer Research Center, Seattle, Washington 98104.
D001424:Bacterial Infections / Q000188:drug therapy* / Q000517:prevention & control; D002440:Cefoxitin / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D002585:Cesarean Section; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy* / Q000517:prevention & control; D006069:Gonorrhea / Q000188:drug therapy; D006801:Humans; D007044:Hysterectomy; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000517:prevention & control; D011292:Premedication
D002440:Cefoxitin